The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Optimizing the cell and gene therapy patient
Please fill out the form below, including the topic you are interested in, and we will be in touch.
Cell and gene therapies have the potential to fundamentally change treatment paradigms for patients living with a wide range of diseases, including genetic disorders, rare cancers, and neurological conditions.
However, to prove their safety and efficacy, cell and gene therapies must make it through a series of clinical trials. Currently, the clinical trial process can be overly complex, which may negatively impact the patient experience of participating.
Some of these challenges can be addressed through innovative research, development, and manufacturing strategies, as well as through patient-centric protocols, which fall under the purview of integrated CRO and CDMO partners.
Our new whitepaper takes a deep dive into these topics, specifically covering:
- The overall importance of patient journey mapping to clinical trial success
- The role of manufacturing in delivering cell and gene therapies to patients
- Future vision for patients participating in cell and gene therapy clinical trials
- Implementation of best practices in cell and gene therapy manufacturing
- The benefits of working with an integrated, end-to-end CRO/CDMO partner
Learn more about these important topics by downloading the whitepaper below.
